Peter Frederick Lang - Mar 18, 2022 Form 4 Insider Report for AERIE PHARMACEUTICALS INC (AERI)

Role: Chief Financial Officer
Signature: /s/ John LaRocca, Attorney-In-Fact for Peter F. Lang
Stock symbol: AERI
Transactions as of: Mar 18, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/22/2022, 08:21 PM
Next filing: Nov 21, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AERI	Common Stock	Award	$0	+46.3K		$0.00	46.3K	Mar 18, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AERI	Stock Option (right to buy)	Award	$0	+161K		$0.00	161K	Mar 18, 2022	Common Stock	161K	$8.80	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares of Common Stock were granted under the Aerie Pharmaceuticals, Inc. Amended and Restated Inducement Award Plan (the "Plan") and are scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, in equal installments on each of the first four anniversaries of March 18, 2022.
F2	This Option was granted under the Plan and is scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, as to 25% of the underlying shares on March 18, 2023 and as to the remaining underlying shares in substantially equal installments on each of the subsequent 36 monthly anniversaries of March 18, 2023.